Publications by authors named "Padmasini Kumar"

Claim this Profile
P
Preclinical Biodistribution and Safety Evaluation of a pbi-shRNA STMN1 Lipoplex after Subcutaneous Delivery.
Zhaohui Wang, Christopher M Jay, Courtney Evans, Padmasini Kumar, Connor Phalon

Toxicol Sci· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.
Jonathan Oh, Minal Barve, Carolyn M Matthews, E Colin Koon, Thomas P Heffernan, Padmasini Kumar

Gynecol Oncol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.
Donald D Rao, Christopher Jay, Zhaohui Wang, Xiuquan Luo, Padmasini Kumar

Mol Ther· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer.
Minal Barve, Zhaohui Wang, Padmasini Kumar, Christopher M Jay, Xiuquan Luo

Mol Ther· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma.
Maurizio Ghisoli, Minal Barve, Reva Schneider, Robert Mennel, Carl Lenarsky, Padmasini Kumar

Mol Ther· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy (FANG™) in advanced cancer of the liver.
John Nemunaitis, Minal Barve, Douglas Orr, Joseph Kuhn, Mitchell Magee, Padmasini Kumar

Oncology· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bifunctional short hairpin RNA (bi-shRNA): design and pathway to clinical application.
Donald D Rao, Neil Senzer, Zhaohui Wang, Padmasini Kumar, Chris M Jay

Methods Mol Biol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer.
Neil Senzer, Minal Barve, Joseph Kuhn, Anton Melnyk, Peter Beitsch, Padmasini Kumar

Mol Ther· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo safety and antitumor efficacy of bifunctional small hairpin RNAs specific for the human Stathmin 1 oncoprotein.
Anagha P Phadke, Chris M Jay, Zhaohui Wang, Salina Chen, Shengnan Liu, Padmasini Kumar

DNA Cell Biol· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine.
Jairo Olivares, Padmasini Kumar, Yang Yu, Phillip B Maples, Neil Senzer

Clin Cancer Res· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.
John Nemunaitis, Robert O Dillman, Paul O Schwarzenberger, Neil Senzer, Casey Cunningham, Padmasini Kumar

J Clin Oncol· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunoglobulin M myeloma: evaluation of molecular features and cytokine expression.
Kartik Konduri, Surinder S Sahota, Gavin Babbage, Alex W Tong, Padmasini Kumar

Clin Lymphoma· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional modulation of smooth muscle cells by the inflammatory mediator CAP37.
Melva L Gonzalez, Xin Ruan, Padmasini Kumar, Paula Grammas, H Anne Pereira

Microvasc Res· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CAP37, a neutrophil-derived inflammatory mediator, augments leukocyte adhesion to endothelial monolayers.
Taunia D Lee, Melva L Gonzalez, Padmasini Kumar, Paula Grammas, H Anne Pereira

Microvasc Res· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activation of microglia: a neuroinflammatory role for CAP37.
H Anne Pereira, Xin Ruan, Padmasini Kumar

Glia· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corneal expression of the inflammatory mediator CAP37.
Xin Ruan, James Chodosh, Michelle C Callegan, Mary C Booth, Taunia D Lee, Padmasini Kumar

Invest Ophthalmol Vis Sci· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CAP37, a novel inflammatory mediator: its expression in endothelial cells and localization to atherosclerotic lesions.
Taunia D Lee, Melva L Gonzalez, Padmasini Kumar, Saritha Chary-Reddy, Paula Grammas

Am J Pathol· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis